Biopsy Device Market Biopsy Device Market: Supporting Early

Biopsy Devices Market to Reach USD 20.04 Billion by 2031 – Exclusive Report by InsightAce Analytic Pvt. Ltd.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on “Global Biopsy Devices Market” (By Product Type (Needle Biopsy Devices (Guidance Systems, Biopsy Consoles, Site Markers, Biopsy Guns (Automated Systems, Semi-Automated Systems), Needles), Skin Biopsy Devices (Punch Biopsy Devices, Shaved Biopsy Devices), Consumables (Forces, Trocars, Trays, Other Consumables), Biopsy Type (Tissue Biopsy (Needle Biopsy, Surgical Biopsy, Skin Biopsy), Liquid Biopsy),

By anatomy (breast, lung, bone, liver, uterus/cervix, abdomen, prostate, heart, skin, other), by disease type (cancer, infections, autoimmune diseases, non-cancer indications, other), by targeting technique (growth contribution analysis, ultrasound-guided biopsy, X-ray-guided biopsy, MRI-guided biopsy, CT-guided biopsy), trends, industry competitive analysis, revenue and forecasts to 2031.

According to the latest research by InsightAce Analytic, the global biopsy devices market is valued at USD 6.03 billion in 2022 and is projected to reach USD 20.04 billion by 2031, registering a compound annual growth rate (CAGR) of 14.39% during the forecast period of 2024-2031.

Request for free sample pages: https://www.insightaceanalytic.com/request-sample/2228

A biopsy is a medical procedure that plays a key role in identifying and removing potentially cancerous tissue. This test involves taking samples of tissue from a suspected area to diagnose cancer. There are different biopsy techniques, such as skin biopsy, vacuum biopsy, incisional and excisional biopsy, fine needle biopsy, and shear biopsy.

The global increase in cancer incidence across all types has significantly increased the need for better care and awareness of screening and diagnostic tools. As a result, the demand for biopsy devices is expected to increase significantly in the coming years.

Several factors are driving this growth in the biopsy market. First, the rising incidence of cancers, especially lung, prostate, and breast cancers, directly translates into a higher demand for biopsy procedures. Second, rapid advancements in biopsy technology, such as 3D optical biopsies, MRI-guided biopsies, and ultrasound-guided biopsies, are further driving the market growth. Lastly, the growing knowledge in chronic disease diagnostics requires integrated biopsy technologies, such as stereotactic-guided biopsies. These factors collectively contribute to the promising prospects for the biopsy market.

List of top players in the biopsy devices market:

• F. Hoffmann-La Roche Sp. z o. o.
• Illumina, Inc.
• Micronome
• QIAGEN
• Revvity, Inc.
• Sysmex Corporation
• Thermo Fisher Scientific Inc
• Argon Medical Devices, Inc.
• B. Braun SE
• Becton
• Dickinson and Co.
• Boston Scientific Corporation
• Cardinal Health, Inc.
• Cook Incorporated Group
• Conmed Corporation
• FUJIFILM Holdings Corporation
• GE Healthcare
• Inrad, Inc.
• Medtronic Sp. z o. o.
• Olympus Corporation
• Siemens Healthineers AG
• Stryker Corporation
• Zamar Care
• Changzhou Jiuhong Medical Instrument Co., Ltd.
• Kind regards (KDL) Meditech
• Ningbo Xinwell Medical Technology Co., LTD.
• Shenzhen Manners Technology Co., Ltd.
• Zhejiang Soudon Medical Technology Co., Ltd
• Agilent Technologies, Inc.
• BGI Group
• Biocept, Inc.
• Bio-Rad Laboratories, Inc.
• Dxcover Limited
• Elypta Limited

Market dynamics:

Drivers-
Various dynamic aspects are driving the growth, trends, and innovations in the biopsy device market. These dynamics are driven by the changing healthcare landscape, technological improvements, legislative changes, and rising prevalence of chronic diseases. There has been a huge increase in the number of cancer patients worldwide.

According to GLOBOCAN projections, the number of cancer patients is expected to increase to 19.3 million by 2025, up from 19.3 million in 2020. Cancer is the second leading cause of death in the United States, accounting for about one in four deaths. According to the American Cancer Society, more than 1,688,000 new cases of cancer (excluding carcinoma in situ at any site) are predicted to be diagnosed in the United States in 2017, and 600,920 cancer-related deaths are expected in the same year; this number translates to 1,650 deaths per day.

Challenges:
The high cost of biopsy tools is restricting the market expansion. Moreover, clinical difficulties in core needle biopsy and rising complaints regarding breast cancer screening procedures are expected to impact the biopsy tools market throughout the projection period. Moreover, biopsy methods help radiologists and surgeons to examine abnormalities at a specific site. However, since these procedures involve cuts and incisions to collect tissue samples, patients may get infected. Increased risk of infection after biopsy procedures may hinder the market growth.

Regional trends:
The North America biopsy device market is expected to register a significant market share in terms of revenue and is projected to grow at a high CAGR in the near future due to the significant availability of skilled medical personnel, availability of well-developed infrastructure, and presence of most of the key stakeholders. Asia Pacific is expected to witness significant growth over the forecasted time period due to the large population, rising disposable income, and increased patient awareness regarding disease screening. Moreover, the growth of the senior population, which is extremely susceptible to cancer, is the major driver of market growth in the region.

Curious about This Latest Version of the Report? Ask Before You Buy: https://www.insightaceanalytic.com/enquiry-before-buying/2228

Last changes:

• In September 2023, a revolutionary collaboration was announced between Roche France, Foundation Medicine and Institute Gustave Roussy to provide in-house liquid biopsy genomic testing to cancer patients in France. By transferring FoundationOne®Liquid CDx technology to Institute Gustave Roussy, Roche France and Foundation Medicine have the potential to provide liquid biopsy testing for comprehensive genomic profiling (CGP) to all patients in France diagnosed with advanced cancer.

• In August 2022, Mammotome announced the release of the Mammotome DualCoreTM Biopsy System, the company’s first dual-stage core biopsy device. This innovative core biopsy device complements Mammotome’s portfolio of ultrasound-guided breast biopsy devices, which already includes the Mammotome® Elite Tetherless Vacuum-Assisted Biopsy Device (VABB tetherless) and the Mammotome RevolveTM Dual Vacuum-Assisted Breast Biopsy System (VABB tethered).

Biopsy Devices Market Segmentation
By product type-
• Needle biopsy devices
o Guidance systems
About Biopsy Consoles
o Place Markers
About Biopsy Guns
 Automated systems
 Semi-automatic systems
about Needles
• Skin biopsy devices
o Punch biopsy tools
About Shave Biopsy Tools
• Consumables
About Ticks
about Trocars
About Trays
o Other consumables
By type of biopsy
• Tissue biopsy
o Needle biopsy
o Surgical biopsy
o Skin biopsy
• Liquid biopsy
Through Anatomy-
• Breast
• Lung
• Bone
• Liver
• Uterus/Cervix/
• Belly
• Prostate
• Cardiology
• Skin
• Others
By type of disease-
• Cancer
• Infections
• Autoimmune diseases
• Non-cancer indications
• Others
According to the conduction technique –
• Growth and share analysis
• Ultrasound guided biopsy
• X-ray guided biopsy
• MRI guided biopsy
• Computed tomography guided biopsy
By region-
North America-
• United States
• Canada
• Mexico
Europe-
• Germany
• Great Britain
• France
• Italy
• Spain
• Rest of Europe
Asia Pacific
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East and Africa-
• Gulf Cooperation Council Countries
• South Africa
• Rest of Middle East and Africa

For more personalization options, visit: https://www.insightaceanalytic.com/report/biopsy-devices-market/2228

Contact us:
InsightAce Analytic Pvt. Ltd
Phone: +1 718 593 4405
Email address: [email protected]
On-site visit: www.insightaceanalytic.com
Follow us on LinkedIn @ bit.ly/2tBXsgS
Follow us on Facebook @ bit.ly/2H9jnDZ

About us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions.
Our qualitative and quantitative market intelligence solutions demonstrate the need to acquire market and competitive information for business development.
We help clients gain competitive advantage by identifying untapped markets, exploring new and competitive technologies, segmenting potential markets and repositioning products.
Our specialty is delivering aggregated and customized market reports with in-depth analysis and key market information in a timely and cost-effective manner.

This version was published on openPR.